Semaglutide vs GHRP-2

Semaglutide and GHRP-2 represent divergent classes of research peptides with minimal mechanistic overlap. Semaglutide is a long-acting GLP-1 receptor agonist developed for metabolic disorders, supported by extensive phase 3 trials and FDA approval for diabetes, obesity, and non-cirrhotic MASH. In contrast, GHRP-2 is a synthetic hexapeptide that acts as a ghrelin receptor agonist to stimulate growth hormone release, primarily used in Japan as a diagnostic agent for GH deficiency. Their research applications target different systems: Semaglutide is studied for weight management, glycemic control, and cardiovascular outcomes, while GHRP-2 is investigated for body composition and endocrine function. This comparison highlights their distinct mechanisms, evidence levels, and safety profiles to help researchers navigate tradeoffs in experimental design.

Semaglutide is a GLP-1 receptor agonist with 94% sequence homology to human GLP-1, conferring resistance to DPP-4 degradation and a half-life of approximately one week. Its molecular weight is ~4113.6 g/mol (C187H291N45O59). Developed by Novo Nordisk and first FDA-approved on December 5, 2017, it is indicated for type 2 diabetes (Ozempic), chronic weight management (Wegovy), and non-cirrhotic MASH. The evidence base is exceptionally robust, anchored by the STEP and SUSTAIN trial programs involving thousands of patients, demonstrating significant weight loss, improved glycemic control, and reduced cardiovascular risk. No generic semaglutide is approved, and the FDA has issued warnings about counterfeit products. Key research claims include dose-dependent reductions in body weight, HbA1c lowering, and decreased major adverse cardiovascular events in at-risk populations.

GHRP-2 (pralmorelin) is a synthetic hexapeptide (D-Ala-D-2-Nal-Ala-Trp-D-Phe-Lys-NH2, MW ~817.97 g/mol) that acts as a potent agonist at the ghrelin receptor (GHS-R), stimulating dose-dependent growth hormone release. It is considered more potent than GHRP-6 with less appetite stimulation and lower elevations of cortisol and prolactin. Approved in Japan as a diagnostic agent for GH deficiency, it has been used clinically in GH-deficient children for 8–24 months with maintained efficacy on growth velocity. Clinical studies report a placebo-like safety profile at therapeutic doses. Key research claims include robust GH release, utility as a diagnostic tool, and sustained efficacy in long-term endocrine studies. However, its evidence base is narrower than semaglutide, with fewer large-scale trials and no FDA approval for therapeutic use outside Japan.

Semaglutide and GHRP-2 target distinct research domains with minimal overlap. Semaglutide is primarily studied in metabolic and cardiovascular contexts, including weight management, glycemic control, and cardiovascular risk reduction. Its applications extend to non-alcoholic steatohepatitis (MASH) and potential neuroprotective effects. GHRP-2, by contrast, is focused on endocrine research, particularly growth hormone secretion, body composition, and diagnostic testing for GH deficiency. While both may influence body composition indirectly—semaglutide via weight loss and GHRP-2 via GH-mediated anabolism—their mechanisms and endpoints differ fundamentally. Researchers should select based on whether the study aims to modulate incretin pathways (semaglutide) or the GH/IGF-1 axis (GHRP-2).

Semaglutide safety is well-characterized from large trials. Common adverse events (≥5%) include nausea, vomiting, diarrhea, abdominal pain, and constipation, which are dose-dependent and often transient. Additional effects include dyspepsia, flatulence, bloating, anorexia, headache, and fatigue. Serious but rare events include pancreatitis, gallbladder disease, and severe allergic reactions. GHRP-2 is generally well-tolerated with a placebo-like safety profile at therapeutic doses in clinical studies. It may increase appetite, though less than GHRP-6, and can elevate cortisol and prolactin levels to a lesser degree. Long-term safety data for GHRP-2 are more limited than for semaglutide, reflecting its narrower clinical use. Researchers should weigh the extensive safety database of semaglutide against the more benign but less studied profile of GHRP-2.